All In Biotech

Drug Trial Radar · NCT04977986

Clinical Study of Cannabidiol in Children, Adolescents, and Young Adults With Fragile X Syndrome

A Randomized, Double-Blind, Placebo-Controlled, Multiple-Center, Efficacy and Safety Study of ZYN002 Administered as a Transdermal Gel to Children, Adolescents and Young Adults With Fragile X Syndrome - RECONNECT

Last checked: Nov 20, 2026Latest source record: Sep 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 257 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

257

Actual

Start

Sep 13, 2021

Primary completion

Aug 29, 2025

Study completion Aug 29, 2025

Sponsor

Sponsor type
Industry
First posted
Jul 27, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 3 years, up to 29 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled, multiple-center study, to assess the efficacy and safety of cannabidiol administered as ZYN002 for the treatment of children, adolescent, and young adult patients with Fragile X syndrome (FXS). Eligible participants will participate in up to an 18-week treatment period, where all participants will receive placebo or active study drug. Patients ages 3 to \< 30 years will be eligible to participate.

Conditions

  • Fragile X Syndrome
  • Fragile X Syndrome (FXS)

Interventions

  • ZYN002Drug

    Pharmaceutically manufactured cannabidiol formulated as a clear gel that can be applied to the skin (transdermal delivery)

  • PlaceboDrug

    Placebo formulated as a clear gel that can be applied to the skin (transdermal delivery) Other Names: Placebo Comparator Matching Placebo

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Aberrant Behavior Checklist-Community Fragile X Factor Structure (ABC-C FXS) Pre-specified Subscale 1 score in patients with complete methylation of the FMR1 gene.Time frame: Change from Baseline to Week 18

Locations

27 sites in 5 countries. Site status is shown where the registry gives one.

  • Phoenix Children's Hospital

    Phoenix, Arizona

  • Science 37

    Culver City, California

  • Amnova Clinical Research, LLC

    Irvine, California

  • Thompson Autism Center CHOC

    Orange, California

  • UC Davis Health System, MIND Institute

    Sacramento, California

  • Children's National Medical center

    Washington D.C., District of Columbia

  • University of Miami

    Miami, Florida

  • Rare Disease Research

    Atlanta, Georgia

  • Rush University Medical Center

    Chicago, Illinois

  • Kennedy Krieger Institute

    Baltimore, Maryland

  • Boston Children's Hospital

    Boston, Massachusetts

  • University of Minnesota Fragile X Clinic (Voyager Clinic)

    Minneapolis, Minnesota

  • University of Mississippi

    Jackson, Mississippi

  • The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics

    New York, New York

  • Central States Research

    Tulsa, Oklahoma

  • Penn State Hershey Medical Center

    Hershey, Pennsylvania

  • Greenwood Genetic Center

    Greenville, South Carolina

  • Primary Children's Hospital

    Salt Lake City, Utah

  • Westmead Children's Hospital

    Sydney, New South Wales, Australia

  • Lady Cilento Children's Hospital - South Brisbane

    Brisbane, Queensland, Australia

  • Genetics Clinics Australia

    Melbourne, Victoria, Australia

  • Wellcome HRB Clinical Research Facility

    Dublin, Ireland

  • Health New Zealand - Te Whatu Ora - Wellington Hospital

    Newtown, Wellington Region, New Zealand

  • University of Edinburgh

    Edinburgh, United Kingdom

  • Leicester Clinical Research

    Leicester, United Kingdom

  • King's College

    London, United Kingdom

  • Manchester University NHS Foundation Trust

    Manchester, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.